Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company

Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups

Fineline Cube Dec 6, 2022

Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...

Company Deals

Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets

Fineline Cube Dec 6, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...

Company Drug

WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 5, 2022

Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...

Company Drug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

Fineline Cube Dec 5, 2022

China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...

Company Deals Digital

China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma

Fineline Cube Dec 5, 2022

China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...

Company Drug

Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study

Fineline Cube Dec 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...

Company Drug

Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...

Company Medical Device

Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA

Fineline Cube Dec 5, 2022

Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...

Company Drug

Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China

Fineline Cube Dec 5, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...

Company Drug

Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia

Fineline Cube Dec 5, 2022

A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...

Company Drug

Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx

Fineline Cube Dec 5, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...

Company Drug

Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Company Drug

Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study

Fineline Cube Dec 5, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...

Company Deals

Tsingke Biotech Secures RMB 400M Series B Financing for Expansion

Fineline Cube Dec 5, 2022

Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...

Company Deals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

Fineline Cube Dec 5, 2022

China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...

Company Deals

SAFE Raises RMB 500M in Series D Financing to Expand CRO Services

Fineline Cube Dec 5, 2022

Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...

Company Medical Device

Peijia Medical Enrolls First Patient in GeminiOne TEER System Study

Fineline Cube Dec 5, 2022

China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...

Posts pagination

1 … 588 589 590 … 663

Recent updates

  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.